Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esther H Zhou

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Drug Safety|July 31, 2024
Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA LabelingGeorge A Neyarapally, Leihong Wu, Joshua Xu, et al.
Journal of Clinical Pharmacology|November 20, 2018
Dosing Recommendations for Quetiapine When Coadministered With HIV Protease InhibitorsMario R Sampson, Kelly Y Cao, Paula L Gish, et al.
Clinical Drug Investigation|May 28, 2025
Trends in US Pediatric Unintentional Nonprescription Cold and Cough, Analgesic and Antipyretic Drug Exposure Cases amid the COVID-19 PandemicSara Karami, Christian Angelo I Ventura, Ellen Pinnow, et al.
Pharmacoepidemiology and Drug Safety|November 27, 2013
Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockersDavid J Graham, Esther H Zhou, Stephen McKean, et al.
Drug Safety|July 15, 2019
Multimodal Analysis of FDA Drug Safety Communications: Lessons from ZolpidemAaron S Kesselheim, Michael S Sinha, Eric G Campbell, et al.
Clinical Toxicology (Philadelphia, Pa.)|February 18, 2026
Intentional pediatric nonprescription cold/cough and analgesic/antipyretic exposure trends amid the COVID-19 pandemicSara Karami, Christian Angelo I Ventura, Ellen Pinnow, et al.
Drug Safety|March 2, 2017
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative StudyAaron S Kesselheim, Sarah A McGraw, Sara Z Dejene, et al.
Drug Safety|January 27, 2026
Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 PandemicCatherine S Hwang, Zhigang Lu, Massimiliano Russo, et al.
Pharmacoepidemiology and Drug Safety|November 5, 2015
Trends in rates of acetaminophen-related adverse events in the United StatesJacqueline M Major, Esther H Zhou, Hui-Lee Wong, et al.
Drug Safety|May 16, 2024
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020Mufaddal Mahesri, Ameet Sarpatwari, Krista F Huybrechts, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Drug Safety|July 31, 2024
Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA LabelingGeorge A Neyarapally, Leihong Wu, Joshua Xu, et al.
Journal of Clinical Pharmacology|November 20, 2018
Dosing Recommendations for Quetiapine When Coadministered With HIV Protease InhibitorsMario R Sampson, Kelly Y Cao, Paula L Gish, et al.
Clinical Drug Investigation|May 28, 2025
Trends in US Pediatric Unintentional Nonprescription Cold and Cough, Analgesic and Antipyretic Drug Exposure Cases amid the COVID-19 PandemicSara Karami, Christian Angelo I Ventura, Ellen Pinnow, et al.
Pharmacoepidemiology and Drug Safety|November 27, 2013
Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockersDavid J Graham, Esther H Zhou, Stephen McKean, et al.
Drug Safety|July 15, 2019
Multimodal Analysis of FDA Drug Safety Communications: Lessons from ZolpidemAaron S Kesselheim, Michael S Sinha, Eric G Campbell, et al.
Clinical Toxicology (Philadelphia, Pa.)|February 18, 2026
Intentional pediatric nonprescription cold/cough and analgesic/antipyretic exposure trends amid the COVID-19 pandemicSara Karami, Christian Angelo I Ventura, Ellen Pinnow, et al.
Drug Safety|March 2, 2017
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative StudyAaron S Kesselheim, Sarah A McGraw, Sara Z Dejene, et al.
Drug Safety|January 27, 2026
Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 PandemicCatherine S Hwang, Zhigang Lu, Massimiliano Russo, et al.
Pharmacoepidemiology and Drug Safety|November 5, 2015
Trends in rates of acetaminophen-related adverse events in the United StatesJacqueline M Major, Esther H Zhou, Hui-Lee Wong, et al.
Drug Safety|May 16, 2024
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020Mufaddal Mahesri, Ameet Sarpatwari, Krista F Huybrechts, et al.
Pageof 5